The biopharma job market in the United States has become increasingly competitive, according to findings from the upcoming BioSpace 2026 U.S. Life Sciences Employment Outlook report. The report is based on a survey conducted late last year among 1,499 biotech and pharmaceutical professionals.
Among those surveyed who are currently employed or working as contractors, 52% said they were actively looking for new jobs, an increase from 46% in 2024. Additionally, 64% indicated plans to look for new roles this year, compared with 59% who intended to do so in 2025. Unemployed respondents also reported high levels of job-seeking activity: 93% were actively searching when surveyed (up from 91% in 2024), and 96% planned to continue their search this year (compared with 95% for the previous year).
Respondents expressed frustration about the number of applicants per position and limited job availability. One participant stated, “There are so many people applying for one job it is insane. It’s almost like a needle in a haystack actually getting an offer.”
Data collected by BioSpace showed that throughout last year, applications submitted each month far exceeded the number of open positions posted on its website. The disparity was most pronounced between May and July, when applications outnumbered live jobs by factors ranging from approximately 4.3 to 4.7 times.
This period coincided with significant layoffs across the industry. From May through July alone, BioSpace tracked that around 68 companies announced or projected layoffs affecting about 15,200 employees. This figure represented more than a third of all staff affected by layoffs or projected cuts in biopharma during the year—a notable increase over prior years.
Additionally, budget reductions at federal agencies impacted thousands of FDA and NIH employees during the first half of the year.
Survey participants cited these layoffs as driving increased competition for fewer available positions. Comments included: “Very few jobs available with a huge pool of candidates looking for a job,” and “Worried that a typical Research/ Discovery leadership job is almost impossible to find due to extreme numbers of unemployed scientists.”
Some described their experience as “an exhausting race for survival.” One respondent wrote: “If companies do not make an effort to up-skill people, the market will undermine itself in the long run, as scientists become increasingly unable to compete in their own field and companies will continue to look for a ‘needle in a haystack’ candidate for each position, making matters worse for both parties.”
Other comments reflected anxiety about re-entering the workforce after gaps or later-career stages:
“Due to my age, gap in experience, and the number of qualified people looking for work, I am uncertain I will be given the opportunity to rejoin the work I am passionate about.”
“I’m unemployed. Two of my friends from my PhD program at Princeton are unemployed. We’re not complete idiots, I don’t think, but nobody wants us."
“I just hope I can find a job at someplace better than Mickey D’s.”
Despite concerns about how long current conditions may persist, two industry experts told BioSpace last November that improvement could begin later this year.
Research and development remains the most sought-after function among both employed/contract workers and unemployed professionals; nearly half (49%) indicated R&D as their preferred area for future employment opportunities.
BioSpace data showed that competition was especially strong within science/R&D functions last year—with monthly application volumes averaging roughly six times higher than open positions posted online.
Technology roles—including artificial intelligence/machine learning—were also highly sought after: ranked second among employed/contract respondents (26%) and third among unemployed professionals (24%). Clinical roles rounded out top choices alongside quality assurance/control functions.
Competition was highest within IT-related roles where applications averaged nearly seven times more than available jobs each month; quality assurance/control saw lower ratios but still had close to three applicants per open role monthly on average.
Amid these challenges some professionals are considering leaving biopharma altogether; among unemployed respondents surveyed by BioSpace,85% said they were contemplating careers outside life sciences.
One commented: “Don’t see biopharma as a viable long term career opportunity any longer.” Another wrote: “I am considering changing industries but I don’t know what else I could do that would be stimulating and pay enough.” A third added: “There is zero job security in biopharma… I wish I had picked a different field of study and work.”
Layoff statistics referenced exclude contract development/manufacturing organizations or medical device firms; figures are compiled using company press releases along with regulatory filings such as WARN Act notices.
